Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
32 pending office actions • 16 art units • 29 examiners • 0 of 32 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
AbbVie Inc. has 32 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 29 distinct examiners, showing very little examiner overlap within the current pending set. The portfolio is distributed across 16 distinct art units, which suggests a high degree of technical specialization for each application.
RICCI, CRAIG D is the busiest examiner for the company, currently responsible for 3 pending office actions. With 32 total pending office actions and 29 distinct examiners, the company rarely has the opportunity to apply lessons learned from one examiner to another pending case. The involvement of 16 distinct art units indicates that AbbVie's biotechnological innovations are being reviewed by many different specialized groups at the USPTO. This requires the prosecution team to navigate 29 different examiner perspectives across 16 specialized divisions, necessitating a highly tailored approach for each filing.
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (12%) |
| §103 only | 7 (22%) |
| §112 only | 3 (9%) |
| Double-patenting only | 2 (6%) |
| Double-patenting + other | 3 (9%) |
| Multi-statute (no §101) | 11 (34%) |
| No statute on record | 2 (6%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RICCI, CRAIG D | 3 | 53.5% | +52.7% |
| FREDRICKSON, COURTNEY B | 2 | 75.6% | +29.5% |
| JANOSKO, CHASITY PAIGE | 1 | 15.9% | +63.6% |
| BAEK, BONG-SOOK | 1 | 41.7% | +69.9% |
| DOUBRAVA, JOHN A | 1 | 76.9% | +26.4% |
| BASQUILL, SEAN M | 1 | 38.8% | +21.7% |
| AZPURU, CARLOS A | 1 | 83.8% | +10.7% |
| CRAIGO, BAHAR ALAWI | 1 | 47.1% | +27.3% |
| BERKE-SCHLESSEL, DAVID W | 1 | 66.7% | +31.8% |
| DAVISON, LAURA L | 1 | 32.6% | +36.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18476916 | METHODS OF TREATING HIDRADENITIS SUPPURATIVA | RZECZYCKI, PHILLIP MATTHEW | 9d |
| 18599800 | USE OF ALPHA-2-ADRENERGIC RECEPTOR AGONISTS FOR IMPROVING VISION | AZPURU, CARLOS A | 27d |
| 18972793 | USE OF BOTULINUM TOXINS FOR THE TREATMENT OF PLATYSMA PROMINENCE | JANOSKO, CHASITY PAIGE | — |
| 18646562 | INJECTION DEVICE | DOUBRAVA, JOHN A | — |
| 18611454 | OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCESS | BASQUILL, SEAN M | — |
| 18437633 | NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONS | BERKE-SCHLESSEL, DAVID W | — |
| 18890599 | CLOSTRIDIUM BOTULINUM NEUROTOXIN SEROTYPE A COMPOSITIONS | SAIDHA, TEKCHAND | — |
| 18809439 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | WILSON, JERICA KATLYNN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17325900 | METHODS OF TREATING HEAVY MENSTRUAL BLEEDING | RICCI, CRAIG D | 13d |
| 18431278 | DUAL CAP SYSTEM FOR CONTAINER-CLOSURES TO MAINTAIN TIP STERILITY DURING SHELF STORAGE | DAVISON, LAURA L | 22d |
| 18599800 | USE OF ALPHA-2-ADRENERGIC RECEPTOR AGONISTS FOR IMPROVING VISION | AZPURU, CARLOS A | 27d |
| 19417018 | SODIUM CHLORITE COMPOSITIONS WITH ENHANCED ANTI-MICROBIAL EFFICACY AND REDUCED TOXICITY | RICCI, CRAIG D | — |
| 18972793 | USE OF BOTULINUM TOXINS FOR THE TREATMENT OF PLATYSMA PROMINENCE | JANOSKO, CHASITY PAIGE | — |
| 18813414 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | BAEK, BONG-SOOK | — |
| 18646562 | INJECTION DEVICE | DOUBRAVA, JOHN A | — |
| 18611454 | OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCESS | BASQUILL, SEAN M | — |
| Art Unit | Apps |
|---|---|
| 1611 | 4 |
| 1623 | 3 |
| 1617 | 2 |
| 1614 | 1 |
| 1699 | 1 |
| 1651 | 1 |
| 3993 | 1 |
| 1626 | 1 |
| 3774 | 1 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19417018 | SODIUM CHLORITE COMPOSITIONS WITH ENHANCED ANTI-MICROBIAL EFFICACY AND REDUCED TOXICITY | RICCI, CRAIG D | 1611 | §102DP | Non-Final OA | — | Pending | Dec 11, 2025 |
| 18972793 | USE OF BOTULINUM TOXINS FOR THE TREATMENT OF PLATYSMA PROMINENCE | JANOSKO, CHASITY PAIGE | — | §103§112 | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18813414 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | BAEK, BONG-SOOK | — | §103 | Non-Final OA | — | Pending | Aug 23, 2024 |
| 18646562 | INJECTION DEVICE | DOUBRAVA, JOHN A | — | §103§112 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18611454 | OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCESS | BASQUILL, SEAN M | 1614 | §103§112 | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18599800 | USE OF ALPHA-2-ADRENERGIC RECEPTOR AGONISTS FOR IMPROVING VISION | AZPURU, CARLOS A | 1617 | §102§103Other | Non-Final OA | 27d | Pending | Mar 08, 2024 |
| 18582331 | DERMAL FILLER COMPOSITIONS | CRAIGO, BAHAR ALAWI | 1699 | DP | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18437633 | NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONS | BERKE-SCHLESSEL, DAVID W | 1651 | §103§112Other | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18431278 | DUAL CAP SYSTEM FOR CONTAINER-CLOSURES TO MAINTAIN TIP STERILITY DURING SHELF STORAGE | DAVISON, LAURA L | 3993 | §103Other | Non-Final OA | 22d | Pending | Feb 02, 2024 |
| 18478718 | AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDERECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | AGUIRRE, AMANDA L | 1626 | DP | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18015136 | TISSUE EXPANSION DEVICE WITH FLUID COLLECTION | DUDDEN, TERESA MARIE | 3774 | §103 | Non-Final OA | 4d overdue | Pending | Jan 09, 2023 |
| 17789162 | CROSSLINKED HA-COLLAGEN HYDROGELS AS DERMAL FILLERS | ISNOR, ALEXANDRA NICOLE | 1611 | §103Other | Final Rejection | 16d overdue | Pending | Jun 24, 2022 |
| 19189086 | RISANKIZUMAB COMPOSITIONS | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | — | Pending | Apr 24, 2025 |
| 18890599 | CLOSTRIDIUM BOTULINUM NEUROTOXIN SEROTYPE A COMPOSITIONS | SAIDHA, TEKCHAND | 1652 | §102§112 | Non-Final OA | — | Pending | Sep 19, 2024 |
| 18809439 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | WILSON, JERICA KATLYNN | — | §101§103Other | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18753308 | DEVICES AND METHODS FOR DELIVERING A BENEFICIAL AGENT TO A USER | FREDRICKSON, COURTNEY B | — | §102§103§112Other | Non-Final OA | — | Pending | Jun 25, 2024 |
| 18742823 | BROMODOMAIN INHIBITORS | SHIAO, YIH-HORNG | — | §101§112DP | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18670261 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | LI, RUIXIANG | — | §101§112 | Non-Final OA | — | Pending | May 21, 2024 |
| 18661199 | SEALING ARRANGEMENT FOR SYRINGE | SHAH, NILAY J | — | §101§103 | Non-Final OA | — | Pending | May 10, 2024 |
| 18251079 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | RAO, PADMAJA S | 1627 | §102§103§112 | Non-Final OA | — | Pending | Apr 28, 2024 |
| 18627239 | DOSING REGIMENS FOR USE IN PREVENTING RELAPSE OF ACUTE MYELOID LEUKEMIA FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE | GALSTER, SAMUEL LEONARD | — | §103 | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18590729 | SELECTIVE REDUCTION OF ANTIBODIES | VAN DRUFF, SYDNEY | — | §102§103 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18489058 | DEVICES AND METHODS FOR DELIVERING A BENEFICIAL AGENT TO A USER | FREDRICKSON, COURTNEY B | 3783 | §112 | Non-Final OA | — | Pending | Oct 18, 2023 |
| 18482794 | COCRYSTALS OF UPADACITINIB | CLARK, AMY LYNN | 1628 | §112 | Final Rejection | — | Pending | Oct 06, 2023 |
| 18476916 | METHODS OF TREATING HIDRADENITIS SUPPURATIVA | RZECZYCKI, PHILLIP MATTHEW | 1625 | §102§103§112 | Non-Final OA | 9d | Pending | Sep 28, 2023 |
| 18463183 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | O DELL, DAVID K | 1621 | §103DP | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18462918 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | NOLAN, JASON MICHAEL | 1623 | Other | Final Rejection | 118d overdue | Pending | Sep 07, 2023 |
| 18317725 | METHODS OF TREATING HEAVY MENSTRUAL BLEEDING | RICCI, CRAIG D | 1611 | §103DP | Non-Final OA | — | Pending | May 15, 2023 |
| 17995798 | METHODS OF TREATING DIABETIC KIDNEY DISEASE | SCHACHERMEYER, SAMANTHA LYNN | 1693 | §102§103 | Final Rejection | — | Pending | Oct 07, 2022 |
| 17807292 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CHENG, KAREN | 1623 | §103 | Final Rejection | 146d overdue | Pending | Jun 16, 2022 |
| 17446807 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | SHTERENGARTS, SAMANTHA L | 1623 | §112 | Non-Final OA | — | Pending | Sep 02, 2021 |
| 17325900 | METHODS OF TREATING HEAVY MENSTRUAL BLEEDING | RICCI, CRAIG D | 1611 | Other | Non-Final OA | 13d | Pending | May 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial